Nonerosive Reflux Disease

To honor GERD Awareness Week on Nov. 24 to 30, the International Foundation for Gastrointestinal Disorders launched a campaign theme, “Relief Starts with Awareness,” to boost understanding of symptoms and treatments for the disease.

PHILADELPHIA — On-demand vonoprazan effectively reduced heartburn symptom severity in patients with nonerosive reflux disease within 1 hour of treatment, according to data presented at the ACG Annual Scientific Meeting.

WASHINGTON — Vonoprazan effectively relieved heartburn symptoms in patients with nonerosive reflux disease as early as day 1 of treatment, with results persisting after a 4-week placebo-controlled period through 20 weeks, according to data.